{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:00:51Z","timestamp":1794261651284,"version":"4.9.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eclinm.2025.103213","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T18:05:08Z","timestamp":1746986708000},"page":"103213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2007-343X","authenticated-orcid":false,"given":"Yael","family":"Wolff Sagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noga","family":"Ramot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erez","family":"Battat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Arbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Reges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eclinm.2025.103213_bib1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer--viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103213_bib2","article-title":"Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden: the Obesity and Disease Development Sweden (ODDS) pooled cohort study","volume":"45","author":"Sun","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.eclinm.2025.103213_bib3","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2014.58.4680","article-title":"American Society of Clinical Oncology position statement on obesity and cancer","volume":"32","author":"Ligibel","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103213_bib4","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103213_bib5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00125-011-2051-6","article-title":"Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies","volume":"54","author":"Larsson","year":"2011","journal-title":"Diabetologia"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103213_bib6","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.3748\/wjg.v21.i19.6026","article-title":"Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review","volume":"21","author":"Guraya","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eclinm.2025.103213_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00125-022-05854-8","article-title":"Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England","volume":"66","author":"Ling","year":"2023","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103213_bib8","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/db20-0084","article-title":"Is type 2 diabetes causally associated with cancer risk? evidence from a two-sample Mendelian randomization study","volume":"69","author":"Yuan","year":"2020","journal-title":"Diabetes"},{"issue":"10031","key":"10.1016\/j.eclinm.2025.103213_bib9","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","article-title":"Management of obesity","volume":"387","author":"Bray","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103213_bib10","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00464-013-3127-9","article-title":"Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis","volume":"27","author":"Tee","year":"2013","journal-title":"Surg Endosc"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103213_bib11","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of bariatric surgery with cancer risk and mortality in adults with obesity","volume":"327","author":"Aminian","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103213_bib12","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/oby.23812","article-title":"Long-term cancer outcomes after bariatric surgery","volume":"31","author":"Adams","year":"2023","journal-title":"Obesity"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103213_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1470-2045(09)70159-7","article-title":"Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","volume":"10","author":"Sj\u00f6str\u00f6m","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103213_bib14","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.3390\/ijms24076192","article-title":"Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk","volume":"24","author":"Wilson","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"61","key":"10.1016\/j.eclinm.2025.103213_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jncimonographs\/lgad003","article-title":"Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities","volume":"2023","author":"Playdonn","year":"2023","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103213_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103213_bib17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103213_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106487","article-title":"Exploring factors associated with acquisition and chronicity of infection in bronchiectasis: a population-based study","volume":"185","author":"Shkeiri","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.eclinm.2025.103213_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"issue":"41","key":"10.1016\/j.eclinm.2025.103213_bib20","first-page":"681","article-title":"Mediation analysis in medical research","volume":"120","author":"T\u00f6nnies","year":"2023","journal-title":"Dtsch Arztebl Int"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103213_bib21","article-title":"Comparative risk of obesity-related cancer with glucagon-like protein-1 receptor agonists vs. bariatric surgery in patients with BMI \u2265 35. Meeting Abstract: 2024 ASCO Annual Meeting I","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103213_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11684-024-1094-2","article-title":"Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications","volume":"18","author":"Shi","year":"2024","journal-title":"Front Med"},{"issue":"Suppl 7","key":"10.1016\/j.eclinm.2025.103213_bib23","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/ijo.2008.244","article-title":"Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study","volume":"32","author":"Sj\u00f6str\u00f6m","year":"2008","journal-title":"Int J Obes"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103213_bib24","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1097\/JS9.0000000000001514","article-title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials","volume":"110","author":"Sun","year":"2024","journal-title":"Int J Surg"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103213_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.eclinm.2025.103213_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.eclinm.2025.103213_bib27","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2025.103213_bib28","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.eclinm.2025.103213_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103213_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103213_bib31","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103213_bib32","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3390\/cancers16091625","article-title":"The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-Based cohort study","volume":"16","author":"Ayoub","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2025.103213_bib34","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103213_bib35","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103213_bib36","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1038\/s41591-024-03052-0","article-title":"Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure","volume":"30","author":"Wolff Sagy","year":"2024","journal-title":"Nat Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:28:39Z","timestamp":1759426119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025001452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":35,"alternative-id":["S2589537025001452"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103213","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103213"}}